 |
|
Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
Jong Man Kim
Clin Mol Hepatol. 2021;27(4):562-563. Published online 2021 Sep 23 DOI: https://doi.org/10.3350/cmh.2021.0276
|
|
Citations to this article as recorded by
 Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Satohiro Masuda, Florian Lemaitre, Markus J. Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnso
Therapeutic Drug Monitoring.2024;[Epub] CrossRef Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation
Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
World Journal of Gastrointestinal Surgery.2023; 15(12): 2727. CrossRef Optimal imaging criteria and modality to determine Milan criteria for the prediction of post-transplant HCC recurrence after locoregional treatment
Nieun Seo, Dong Jin Joo, Mi-Suk Park, Seung-seob Kim, Hye Jung Shin, Yong Eun Chung, Jin-Young Choi, Myoung Soo Kim, Myeong-Jin Kim
European Radiology.2022; 33(1): 501. CrossRef
|